Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1IK2CX002822-01A1 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Opioid use disorder (OUD) confers a higher risk of acquiring and transmitting infectious diseases, which may have long-term health consequences in Veterans. Treatment of OUD with medication assisted therapy is highly effective, however this often occurs independently of infectious diseases care. This project will test out a new model that combines infectious diseases and OUD care within one VA clinic appointment. This new care model may improve the health of Veterans and reduce cost and time required for Veterans who often need to attend multiple outpatient appointments.
Opioid use disorder (OUD) is associated with increased risk for overdose as well as acquisition and transmission of infectious diseases (ID), including HIV, hepatitis C virus (HCV), and bacterial sexually transmitted infections (STI). Previous studies support improved clinical outcomes when integrating treatment for OUD and screening and treatment of HIV and HCV in non-Veteran populations. However, clinical care for Veterans with OUD often requires appointments with multiple different healthcare providers. These care silos place an increased burden on this patient population who often have barriers to appointment attendance. Improved integration OUD and ID clinical care is needed. In a recent study of Veterans with OUD who accessed care at the Northport VA (Long Island, NY) the investigators identified 216 (43%) Veterans who had a history of injecting drug use and of those, 134 (62%) had HCV and 30 (13.9%) had at least one severe injection related infection requiring hospitalization. The investigators also found low rates of screening for bacterial sexually transmitted infections, including syphilis (n=371, 74%), gonorrhea (n=160, 31.9%), chlamydia (n=169, 33.7%) and low uptake of HIV pre-exposure prophylaxis (PrEP) (n=4, 0.8%). In this pilot study, the investigators will assess the feasibility and acceptability of an integrated ID screening and PrEP intervention for Veterans with OUD who are engaged in care through the Northport VA SUD clinic. The investigators will randomize Veterans to receive either integrated care (HIV, HCV, STI screening and/or PrEP plus SUD care) or treatment as usual (SUD care plus ID clinic referral). The investigators will also compare rates of HIV, HCV and bacterial STI screening as well as PrEP uptake between the groups. This research will benefit male and female Veterans with OUD. This project will be carried out at the Northport Veterans Affairs Medical Center (NVAMC). Information obtained from this study will be utilized to inform a larger multi-site VA trial assessing the efficacy of IC versus usual care.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Integrated care | Experimental | Study visit 1: Participants will first complete a study interview, then will receive a prescription for laboratory testing for HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), gonorrhea, chlamydia, and syphilis. Those who meet eligibility criteria for PrEP will receive a prescription for PrEP (emtricitabine 200 mg (FTC)/25 mg tenofovir alafenamide-emtricitabine (TAF) or once daily emtricitabine 200 mg (FTC)/300 mg tenofovir disoproxil fumarate-emtricitabine (TDF)), and will be referred to the Infectious Diseases clinic for PrEP follow-up. Participants will then complete a standard SUD clinic appointment. Study visit 2: Participants will follow-up at 90 days in the SUD clinic where they will repeat the study interview, followed by receipt of standard SUD clinical care. |
|
| Treatment as usual | No Intervention | Study visit 1: Participants will first complete a study interview, then will complete a standard SUD clinic appointment. After the SUD appointment, participants will be referred to the Infectious Diseases clinic to receive standard infectious diseases laboratory testing, including HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), gonorrhea, chlamydia, and syphilis. Those who meet eligibility criteria for PrEP will receive a prescription for PrEP (emtricitabine 200 mg (FTC)/25 mg tenofovir alafenamide-emtricitabine (TAF) or once daily emtricitabine 200 mg (FTC)/300 mg tenofovir disoproxil fumarate-emtricitabine (TDF) through the infectious diseases clinic. Study visit 2: Participants will follow-up at 90 days in the SUD clinic where they will repeat the study interview, followed by receipt of their standard SUD clinical care. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Integrated care | Other | Receipt of infectious diseases laboratory testing and/or PrEP for HIV within a single substance use disorder clinic appointment. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Infectious diseases screening uptake during intervention period | Proportion of Veterans who completed any screening for HIV, hepatitis C virus (HCV), gonorrhea, chlamydia, or syphilis during the intervention period | 90 days |
| Measure | Description | Time Frame |
|---|---|---|
| PrEP uptake during intervention period | Proportion who initiated PrEP for HIV during the intervention period | 90 days |
| HIV screening uptake during intervention period | Proportion who completed screening for HIV during the intervention period |
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility of the integrated care intervention | Proportion of Veterans who agreed that the integrated care intervention was a feasible care model for the substance use disorder clinic | 90 days |
| Acceptability of the integrated care intervention |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Audun J Lier, MD | Contact | (631) 261-4400 | 4827 | audun.lier@va.gov |
| Name | Affiliation | Role |
|---|---|---|
| Audun J Lier, MD | Northport VA Medical Center, Northport, NY | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Northport VA Medical Center, Northport, NY | Northport | New York | 11768-2200 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Participants will be randomized to receive either integrated care (infectious diseases screening and/or PrEP for HIV plus opioid use disorder clinical care within one clinic appointment) or treatment as usual (opioid use disorder clinical care plus infectious diseases clinic referral for testing and/or PrEP for HIV)
Not provided
Not provided
Not provided
Not provided
| 90 days |
| HCV screening uptake during intervention period | Proportion who completed screening for HCV during the intervention period | 90 days |
| Gonorrhea screening uptake during intervention period | Proportion who completed screening for gonorrhea during the intervention period | 90 days |
| Chlamydia screening uptake during intervention period | Proportion who completed screening for chlamydia during the intervention period | 90 days |
| Syphilis screening uptake during intervention period | Proportion who completed screening for syphilis during the intervention period | 90 days |
| PrEP uptake during follow-up period | Proportion who initiated PrEP for HIV at any point during the follow-up period | 270 days |
| HIV screening uptake during follow-up period | Proportion who completed screening for HIV at any point during the follow-up period | 270 days |
| HCV screening uptake during follow-up period | Proportion who completed screening for HCV at any point during the follow-up period | 270 days |
| Gonorrhea screening uptake during follow-up period | Proportion who completed screening for gonorrhea at any point during the follow-up period | 270 days |
| Chlamydia screening uptake during follow-up period | Proportion who completed screening for chlamydia at any point during the follow-up period | 270 days |
| Syphilis screening uptake during follow-up period | Proportion who completed screening for syphilis at any point during the follow-up period | 270 days |
| PrEP retention during the intervention period | Proportion of Veterans who adhered to the PrEP prescription during the intervention period | 90 days |
| PrEP retention during the follow-up period | Proportion of Veterans who adhered to the PrEP prescription during the follow-up period | 270 days |
Proportion of Veterans who agreed that the integrated care intervention was an acceptable care model for the substance use disorder clinic
| 90 days |
| ID | Term |
|---|---|
| D009293 | Opioid-Related Disorders |
| D006526 | Hepatitis C |
| D006069 | Gonorrhea |
| D002690 | Chlamydia Infections |
| D013587 | Syphilis |
| D012749 | Sexually Transmitted Diseases |
| ID | Term |
|---|---|
| D000079524 | Narcotic-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D006525 | Hepatitis, Viral, Human |
| D014777 | Virus Diseases |
| D018178 | Flaviviridae Infections |
| D012327 | RNA Virus Infections |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D016870 | Neisseriaceae Infections |
| D016905 | Gram-Negative Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D015231 | Sexually Transmitted Diseases, Bacterial |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D002694 | Chlamydiaceae Infections |
| D014211 | Treponemal Infections |
| D013145 | Spirochaetales Infections |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D019033 | Delivery of Health Care, Integrated |
| ID | Term |
|---|---|
| D003695 | Delivery of Health Care |
| D010346 | Patient Care Management |
| D006298 | Health Services Administration |
| D017530 | Health Care Quality, Access, and Evaluation |
Not provided
Not provided